Mycobacterium avium

Objective. Comparative assessment of in vitro susceptibility of M. avium isolated from patients with mycobacteriosis (MB) with positive and negative HIV status. Materials and Methods. M. avium isolates of were revealed during 2018–2023 from clinical samples of 402 adult patients (≥ 18 years old) in the National Medical Research Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation: 144 strains were isolated from individuals with HIV infection (HIV+) and 258 – from patients with a negative HIV status (HIV-).

Objective. Conduct a comparative assessment of the frequency and spectrum of antimicrobial resistance of Mycobacterium avium isolated from patients of a phthisiopulmonology clinic in the pre-Covid period (2018–2019) and during the COVID-19 pandemic (2020–2023). Materials and Methods. The antimicrobial sensitivity of M. avium isolates was determined to 8 antimicrobial drugs: amikacin, clarithromycin, linezolid, moxifloxacin, ciprofloxacin, doxycycline, rifabutin, rifampicin. Drug susceptibility testing was performed using serial broth microdilution method according to published CLSI guidelines, M24S, 2023.